Capricor Therapeutics Faces Legal Action Over Alleged Misleading Statements on Deramiocel

Capricor Therapeutics Faces Legal Challenges Over Allegations of Misleading Statements

Capricor Therapeutics, Inc. is currently embroiled in legal disputes following allegations of misleading statements related to its lead cell therapy candidate, deramiocel. The Gross Law Firm has issued a notice to shareholders about potential legal action stemming from communications made during the period from October 9, 2024, to July 10, 2025. The firm encourages affected shareholders to reach out for a possible lead plaintiff appointment, emphasizing that participation in recovery does not require this step. The allegations suggest that while Capricor projected optimism regarding obtaining a Biologics License Application (BLA) from the FDA, the company failed to disclose critical adverse information about the safety and efficacy of deramiocel from its Phase 2 HOPE-2 trial.

The crux of the complaints centers on Capricor's assertions about deramiocel's clinical progress. Shareholders claim that the company publicly conveyed a favorable outlook on its chances of FDA approval while being aware of negative data from clinical trials. This culminated in a Complete Response Letter (CRL) from the FDA on July 11, 2025, rejecting the BLA due to insufficient evidence of effectiveness. The fallout from this revelation led to a significant drop in the company’s stock price, highlighting the impact of the alleged misleading statements on investor sentiment and market perception.

In addition to the Gross Law Firm's notice, the DJS Law Group and the Schall Law Firm also announced class action lawsuits against Capricor, alleging violations of the Securities Exchange Act of 1934. These lawsuits underscore the widespread concern among investors regarding the company's communications and the potential ramifications of their decisions based on what they believed to be accurate information. Shareholders are urged to register by September 15, 2025, to ensure they can participate in any recovery efforts.

As the legal proceedings unfold, Capricor faces scrutiny not only from investors but also from regulatory bodies overseeing corporate governance and transparency in the biotechnology sector. The outcome of these lawsuits may have lasting implications for the company’s reputation and its ability to attract future investment, particularly in a competitive field where trust and accuracy in communications are paramount for success.